Catalent

Catalent is a Somerset, New Jersey-based contract development and manufacturing organization (CDMO) founded in 2007 as a spin-off from Cardinal Health that provides advanced formulation, drug delivery technologies, and manufacturing services for pharmaceutical, biotechnology, and consumer health customers. For researchers translating drug candidates from discovery into clinical studies, Catalent offers formulation development services that apply their OptiForm Solution Suite technology to improve the bioavailability of poorly water-soluble compounds through hot melt extrusion, spray drying, lipid formulation, and other solubility enhancement platforms. Their Zydis fast-dissolve oral dosage technology, developed from Leeds University research, produces orally disintegrating tablets for patient compliance research. Catalent's Biologic manufacturing division provides cell line development using their GPEx lentiviral cell engineering technology, which enables stable high-expressing CHO cell line creation, and their biologics manufacturing facilities produce clinical and commercial batches of monoclonal antibodies, bispecifics, and fusion proteins. The company's gene therapy CDMO capabilities have grown through acquisitions of MaSTherCell, Paragon Gene Therapy, and others, providing viral vector manufacturing in AAV, lentivirus, and adenovirus formats for academic gene therapy researchers and clinical programs. Catalent's Softgel technologies, including the RP Scherer innovations, provide research into lipid-based drug delivery systems for oral peptide and oligonucleotide delivery. Their analytical sciences support covers process characterization and forced degradation studies essential for regulatory filings.